Well Referenced

Category: Sexual Health & Hormone Optimization

A systematic review of randomized controlled trials investigating the efficacy and safety of testosterone therapy for female sexual dysfunction in postmenopausal women

This systematic review assesses randomized controlled trials (RCTs) on the efficacy and safety of testosterone therapy for postmenopausal women with sexual dysfunction. Key findings suggest that testosterone improves sexual function and may increase bone mineral density and decrease HDL cholesterol. However, the long-term safety remains unclear. The article aims to

Read More »
June 26, 2025 No Comments

Bioidentical hormone therapy: a review of the evidence

The article evaluates bioidentical hormone therapy (BHT), comparing it to conventional hormone therapy (CHT). While BHT is marketed as a safer alternative, the review emphasizes that there is insufficient scientific evidence to support its claimed benefits and safety. The article urges caution, as the lack of standardized formulations and proper

Read More »
June 26, 2025 No Comments

A woman’s journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement

This article examines the impact of estrogen replacement therapy during menopause, emphasizing its role in mitigating cardiovascular and musculoskeletal risks. It highlights the benefits of estrogen for reducing the risks of coronary heart disease and osteoporosis, particularly with transdermal forms for older women due to a lower risk of thrombosis.

Read More »
June 26, 2025 No Comments

Bioidentical hormones for menopausal therapy

This review discusses the use of bioidentical hormones for menopausal therapy, criticizing the assumption that they are safer than synthetic hormones. Despite some proponents advocating for their use, particularly through salivary hormone testing, the review finds insufficient evidence to support their superiority or safety compared to synthetic options. Providers should

Read More »
June 26, 2025 No Comments

Designing drugs for the treatment of female sexual dysfunction

The article “Designing drugs for the treatment of female sexual dysfunction” (PMID: 17826689) reviews therapeutic strategies for female sexual dysfunction (FSD), which affects approximately 30% of women and includes issues with desire, arousal, and orgasm. Early treatments, modeled after male erectile dysfunction therapies, have largely been ineffective for women, leading

Read More »
June 26, 2025 No Comments

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist

This study evaluated the effect of bremelanotide on sexual arousal and desire in premenopausal women with sexual arousal disorder. Bremelanotide improved both subjective sexual responses and vaginal pulse amplitude compared to a placebo. The treatment was well tolerated, with mild side effects such as nausea and headaches. This research suggests

Read More »
June 26, 2025 No Comments

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

This meta-analysis of 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 without examined the link between hormone replacement therapy (HRT) and breast cancer risk. The findings showed that current HRT use increases breast cancer risk, with the risk rising with prolonged use but diminishing after cessation. The

Read More »
June 26, 2025 No Comments

Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine

The 2019 article “Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine” provides revised clinical guidelines on testosterone deficiency (TD) and its treatment. The recommendations emphasize that symptoms correlate more closely with free testosterone levels than total levels, with treatment consideration for

Read More »
June 26, 2025 No Comments

Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women

This study, published in Menopause in 2010 (PMID: 20632462), investigated the relationship between sex hormone levels and inflammatory markers in postmenopausal women, both undergoing hormone therapy and not. Findings indicate that while hormone therapy can reduce vascular inflammation, oral estradiol therapy raises C-reactive protein (CRP), a marker of generalized inflammation.

Read More »
June 26, 2025 No Comments